{"id":2686,"date":"2014-06-04T22:45:00","date_gmt":"2014-06-04T22:45:00","guid":{"rendered":"https:\/\/cdafound.org\/?p=2686"},"modified":"2025-01-16T15:52:46","modified_gmt":"2025-01-16T15:52:46","slug":"the-disease-burden-of-hepatitis-c-in-belgium-development-of-a-realistic-disease-control-strategy","status":"publish","type":"post","link":"https:\/\/cdafound.org\/fr\/the-disease-burden-of-hepatitis-c-in-belgium-development-of-a-realistic-disease-control-strategy\/","title":{"rendered":"La charge de morbidit\u00e9 de l'h\u00e9patite C en Belgique: d\u00e9veloppement d'une strat\u00e9gie r\u00e9aliste de lutte contre la maladie"},"content":{"rendered":"

R\u00e9sum\u00e9<\/h2>\n\n\n\n

Arri\u00e8re-plan<\/h3>\n\n\n\n

De nouveaux agents antiviraux directs (AAD) seront bient\u00f4t disponibles avec une r\u00e9ponse virale prolong\u00e9e (RVS) plus \u00e9lev\u00e9e, moins d'effets secondaires et une meilleure observance. Notre objectif \u00e9tait d'\u00e9valuer diff\u00e9rentes strat\u00e9gies r\u00e9alistes pour contr\u00f4ler l'augmentation pr\u00e9vue de la charge de morbidit\u00e9 li\u00e9e au VHC en Belgique.<\/p>\n\n\n\n

M\u00e9thodes<\/h3>\n\n\n\n

Sur la base d'une revue de la litt\u00e9rature, d'opinions d'experts et d'hypoth\u00e8ses historiques, la progression de la maladie \u00e0 VHC et la mortalit\u00e9 en Belgique ont \u00e9t\u00e9 mod\u00e9lis\u00e9es jusqu'en 2030. Des strat\u00e9gies explorant l'impact de l'augmentation du traitement, du d\u00e9lai de traitement et des restrictions de traitement ont \u00e9t\u00e9 d\u00e9velopp\u00e9es.<\/p>\n\n\n\n

R\u00e9sultats<\/h3>\n\n\n\n

Bien que la pr\u00e9valence globale du VHC diminue en Belgique, la charge du VHC de stade avanc\u00e9, y compris la cirrhose et le carcinome h\u00e9patocellulaire (CHC), devrait augmenter avec les taux de traitement et de gu\u00e9rison actuels. En augmentant la RVS \u00e0 90% \u00e0 partir de 2016 et le nombre de cas trait\u00e9s (de 710 \u00e0 2050), en 2030, les cas de cirrhose, de cirrhose d\u00e9compens\u00e9e et de CHC seraient nettement inf\u00e9rieurs \u00e0 ceux de 2013. Cette strat\u00e9gie s'est av\u00e9r\u00e9e plus efficace lorsqu'elle est appliqu\u00e9e \u00e0 F2. -F4 cas. Pour obtenir des r\u00e9sultats comparables avec les cas F0-F4, 3 490 patients doivent \u00eatre trait\u00e9s. Un acc\u00e8s retard\u00e9 de deux ans aux AAD a augment\u00e9 la morbidit\u00e9 et la mortalit\u00e9 li\u00e9es au VHC de 15% par rapport \u00e0 notre strat\u00e9gie.<\/p>\n\n\n\n

Conclusions<\/h3>\n\n\n\n

Compte tenu de l'\u00e9volution de la charge de la maladie \u00e0 VHC et de la n\u00e9cessit\u00e9 d'une utilisation efficace des ressources de sant\u00e9, l'application principale des nouveaux AAD en Belgique devrait se concentrer sur les patients atteints de fibrose importante et avanc\u00e9e (F2-F4), en fournissant ces nouveaux m\u00e9dicaments sans d\u00e9lai d\u00e8s leur disponibilit\u00e9 et en am\u00e9liorant l'acc\u00e8s. \u00e0 la th\u00e9rapie.<\/p>\n\n\n\n

Des pays:<\/strong> Belgique<\/p>\n\n

\n
Lire le rapport complet<\/a><\/div>\n<\/div>","protected":false},"excerpt":{"rendered":"

Summary Background Novel direct antiviral agents (DAAs) will become available soon with higher sustained viral response (SVR), fewer side-effects and higher compliance. Our aim was to evaluate different realistic strategies to control the projected increase in HCV-related disease burden in Belgium. Methods Based on literature review, expert opinions and historical assumptions, HCV-disease progression and mortality […]<\/p>\n","protected":false},"author":24,"featured_media":3493,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[9],"tags":[10,12],"publication-author":[2245,1134,2095,494,1136,895,1132,1135],"class_list":["post-2686","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-publication","tag-hcv","tag-modelling","publication-author-hindman-s","publication-author-laleman-w","publication-author-moreno-c","publication-author-razavi-h","publication-author-starkel-p","publication-author-van-damme-p","publication-author-van-vlierberghe-h","publication-author-vandijck-d"],"acf":[],"_links":{"self":[{"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/posts\/2686","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/users\/24"}],"replies":[{"embeddable":true,"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/comments?post=2686"}],"version-history":[{"count":7,"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/posts\/2686\/revisions"}],"predecessor-version":[{"id":7632,"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/posts\/2686\/revisions\/7632"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/media\/3493"}],"wp:attachment":[{"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/media?parent=2686"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/categories?post=2686"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/tags?post=2686"},{"taxonomy":"publication-author","embeddable":true,"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/publication-author?post=2686"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}